Digestive Enzymes: Useful, Overused, Often Unnecessary

← Back to articles

Digestive enzyme supplements are one of the fastest-growing categories in gastrointestinal wellness marketing. The pharmacological rationale that anchors the whole category is real and narrow: when the pancreas cannot make enough lipase, protease, and amylase, food — especially fat — is not absorbed, and replacing those enzymes fixes it. The marketing then quietly stretches that logic to cover anyone who feels bloated after a big meal. The practical question is how often a healthy adult actually has an enzyme deficiency, and the answer is: far less often than the supplement aisle implies. Most enzyme products are sold to people whose pancreas is working fine.

When enzymes are genuinely needed

Pancreatic enzyme replacement therapy (PERT — typically porcine pancreatin or pancrelipase, enteric-coated to survive stomach acid) is the established, non-negotiable treatment for true exocrine pancreatic insufficiency (EPI): cystic fibrosis, chronic pancreatitis, pancreatic cancer, and the state after pancreatic or upper-GI surgery. Here the deficiency is objective, diagnosed by a low faecal elastase-1 (commonly <200 mcg/g) or by direct fat-absorption testing, and the benefit is well documented. A systematic review and meta-analysis of 17 randomised trials in chronic pancreatitis found that PERT significantly improved the coefficient of fat absorption versus both baseline and placebo, with higher doses and enteric coating performing better (de la Iglesia-García 2016). In advanced pancreatic cancer, where EPI is present in roughly 70% of patients, a meta-analysis linked enzyme replacement to a survival benefit of several months alongside a trend toward better quality of life (Iglesia 2020). The recurring real-world problem is the opposite of overuse: patients are routinely under-dosed relative to guideline targets of about 40,000–50,000 lipase units per meal, and underdosing relieves symptoms without fully correcting malnutrition (Kadaj-Lipka 2025; Lewis 2023). In these settings, more enzyme is medicine, not marketing.

In common "bloating" and IBS

Step outside diagnosed pancreatic disease and the evidence for over-the-counter digestive enzymes gets thin. A review of enzyme supplementation across GI disorders noted that animal-derived pancreatic enzymes are an established standard of care for true deficiency, while broader claims rest on small, heterogeneous studies and remain "promising" rather than proven (Ianiro 2016). For functional bloating, gas, and irritable bowel syndrome in people with normal pancreatic function, broad-spectrum blends frequently fail to separate from placebo, and the trials that exist tend to be short and poorly controlled. The defensible exceptions are the enzymes that target a specific, identifiable substrate — lactase for diagnosed lactose intolerance, and alpha-galactosidase for the fermentable carbohydrates in beans and cruciferous vegetables — rather than the everything-everywhere blends.

Substrate-specific enzymes that do work

When an enzyme is matched to the exact molecule a person cannot handle, the data improve markedly. For lactose intolerance, supplemental lactase (tilactase) taken before a lactose load reduced breath-hydrogen and gastrointestinal symptoms significantly versus placebo in a randomised trial (Ojetti 2010) — though it is worth noting that for infant colic, where lactose is often blamed reflexively, a systematic review of randomised trials found lactase did not reliably reduce crying (Kozłowska-Jałowska 2024), a useful reminder that the enzyme only helps when the problem is genuinely the sugar. For the gas produced by beans, a randomised double-blind crossover study showed oral alpha-galactosidase cut breath-hydrogen and flatulence severity after a high-bean meal (Di Stefano 2006). A more specialised case is gluten: an Aspergillus niger prolyl endoprotease (AN-PEP) was shown in a randomised crossover study to degrade most gluten in the stomach of healthy volunteers (Salden 2015). That can blunt the effect of incidental cross-contamination, but it is emphatically not a treatment for coeliac disease, which still requires strict gluten avoidance. Bromelain and papain, plant proteases sold in many blends, are better characterised for anti-inflammatory uses than for digestion, and the generic "broad-spectrum" formula works least reliably precisely because it is not aimed at any one substrate.

The quality problem

Even when the right enzyme is chosen, the product has to actually contain active enzyme by the time you swallow it. Enzyme activity degrades with heat, humidity, and time, so a label that lists activity units (FCC, USP, or IU) for each enzyme is far more informative than one quoting gross milligrams of "enzyme blend." Acid stability matters too: many enzymes are denatured by gastric acid unless they are enteric-coated or formulated to act at gastric pH — one reason prescription pancreatin uses acid-resistant microspheres and is sometimes paired with acid suppression. Cheap "enzyme formulas" can be mostly filler with token activity, and because supplements are not held to drug-grade potency standards, third-party verification is the exception rather than the rule.

Who should actually consider them

The honest shortlist is narrow. People with objective evidence of an enzyme deficiency — a low faecal elastase, a positive lactose breath test, documented malabsorption on workup — benefit from the matched enzyme, and those with diagnosed pancreatic disease need prescription PERT at adequate doses. Exocrine pancreatic function does decline modestly with age, and EPI becomes more common in older adults, so older people with persistent, investigated digestive symptoms are a reasonable group to evaluate (Rothenbacher 2005). For the much larger population of healthy adults with generic bloating, the better levers are usually diet, fibre and FODMAP adjustments, meal size and timing, alcohol, stress, and sleep — not a scoop of enzyme powder on every plate. Persistent or alarming symptoms (weight loss, oily stools, anaemia) deserve a clinician and a workup, not a louder supplement.

Sources

1. de la Iglesia-García D, Huang W, Szatmary P, et al. "Efficacy of pancreatic enzyme replacement therapy in chronic pancreatitis: systematic review and meta-analysis." Gut, 2017;66(8):1354-1355. PMID 27941156. DOI: 10.1136/gutjnl-2016-312529.
2. de la Iglesia D, Avci B, Kiriukova M, et al. "Pancreatic exocrine insufficiency and pancreatic enzyme replacement therapy in patients with advanced pancreatic cancer: A systematic review and meta-analysis." United European Gastroenterology Journal, 2020;8(9):1115-1125. PMID 32631175. DOI: 10.1177/2050640620938987.
3. Kadaj-Lipka R, Monica M, Stożek-Tutro A, Ryś P, Rydzewska G. "Pancreatic Enzyme Replacement Therapy in Pancreatic Exocrine Insufficiency — Real-World's Dosing and Effectiveness: A Systematic Review." Digestive Diseases and Sciences, 2025;70(7):2270-2284. PMID 40169459. DOI: 10.1007/s10620-025-09011-0.
4. Lewis DM, Rieke JG, Almusaylim K, et al. "Exocrine Pancreatic Insufficiency Dosing Guidelines for Pancreatic Enzyme Replacement Therapy Vary Widely Across Disease Types." Digestive Diseases and Sciences, 2024;69(2):615-633. PMID 38117426. DOI: 10.1007/s10620-023-08184-w.
5. Ianiro G, Pecere S, Giorgio V, Gasbarrini A, Cammarota G. "Digestive Enzyme Supplementation in Gastrointestinal Diseases." Current Drug Metabolism, 2016;17(2):187-93. PMID 26806042. DOI: 10.2174/138920021702160114150137.
6. Ojetti V, Gigante G, Gabrielli M, et al. "The effect of oral supplementation with Lactobacillus reuteri or tilactase in lactose intolerant patients: randomized trial." European Review for Medical and Pharmacological Sciences, 2010;14(3):163-70. PMID 20391953.
7. Di Stefano M, Miceli E, Gotti S, Missanelli A, Mazzocchi S, Corazza GR. "The effect of oral alpha-galactosidase on intestinal gas production and gas-related symptoms." Digestive Diseases and Sciences, 2007;52(1):78-83. PMID 17151807. DOI: 10.1007/s10620-006-9296-9.
8. Salden BN, Monserrat V, Troost FJ, et al. "Randomised clinical study: Aspergillus niger-derived enzyme digests gluten in the stomach of healthy volunteers." Alimentary Pharmacology & Therapeutics, 2015;42(3):273-85. PMID 26040627. DOI: 10.1111/apt.13266.
9. Kozłowska-Jałowska A, Stróżyk A, Horvath A, Szajewska H. "Effect of lactase supplementation on infant colic: Systematic review of randomized controlled trials." Journal of Pediatric Gastroenterology and Nutrition, 2024;78(5):1009-1016. PMID 38426798. DOI: 10.1002/jpn3.12144.
10. Rothenbacher D, Löw M, Hardt PD, Klör HU, Ziegler H, Brenner H. "Prevalence and determinants of exocrine pancreatic insufficiency among older adults: results of a population-based study." Scandinavian Journal of Gastroenterology, 2005;40(6):697-704. PMID 16036530. DOI: 10.1080/00365520510023116.